Back to Tirzepatide research
tirzepatide gip agonist other 2025-07-01 ClinicalTrials

GLP-1 Analogues and CBT Explored for Binge Eating and Obesity Management

Behavioral Therapy and GLP-1 Analogue Effects on Binge Eating, Weight, and Coping in Obesity

Background

Patients suffering from both morbid obesity and Binge Eating Disorder (BED) face complex challenges, often requiring comprehensive interventions. Current standard care frequently includes intensive lifestyle treatment programs, featuring individual consultations and structured CBT-E group therapy (Cognitive Behavioral Therapy-Enhanced). However, there remains a critical knowledge gap regarding the comparative and combined efficacy of GLP-1 analogues with these established behavioral therapies, particularly concerning their impact on BED symptomatology and the adoption of coping strategies.

Results

As this study is currently recruiting and has not yet yielded results, its primary objective is to evaluate the impact on BED symptomatology, including the frequency and severity of binge eating episodes. Secondary objectives include examining the potential adoption of alternative harmful coping mechanisms and assessing changes in psychological well-being. Researchers will also meticulously track weight changes and their consequent influence on obesity-associated comorbid conditions. > The study is specifically designed to determine if the addition of a GLP-1 analogue to a comprehensive lifestyle program leads to a significantly greater reduction in BED symptoms and improved coping compared to the lifestyle program alone.

Why It Matters

The insights gained from this study are crucial for advancing personalized treatment strategies for individuals with co-occurring obesity and Binge Eating Disorder. By understanding how GLP-1 analogues interact with behavioral therapy, clinicians could develop more targeted and effective interventions. If successful, this research could lead to the integration of GLP-1 analogues into standard care protocols for BED in obese patients, significantly improving long-term health outcomes and quality of life. The findings will be instrumental in informing the design of future randomized controlled trials, which are essential for establishing causality and optimizing combined therapeutic approaches.


tirzepatide gip agonist glp 1 agonist glp-1r gip-r protocol relevant
Source: clinicaltrials:NCT07042672 · Ingested 2026-04-03 · Digest: gemini-2.5-flash